Kees Hendricksen

Summary

Affiliation: Radboud University Nijmegen Medical Centre
Country: The Netherlands

Publications

  1. pmc Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Inter Mail 659, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    World J Urol 27:337-42. 2009
  2. doi The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations
    Harm C Arentsen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Urol Oncol 30:64-8. 2012
  3. doi Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur Urol 53:984-91. 2008
  4. doi Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer
    Rianne J M Lammers
    Radboud University Nijmegen Medical Center, Department of Urology, Nijmegen, The Netherlands
    Eur Urol 60:713-20. 2011
  5. doi Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    BJU Int 101:889-93. 2008
  6. ncbi Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Curr Opin Urol 17:352-7. 2007
  7. ncbi Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results
    J Alfred Witjes
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur Urol 53:45-52. 2008
  8. ncbi Intravesical gemcitabine: an update of clinical results
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Curr Opin Urol 16:361-6. 2006
  9. pmc Experimental rat bladder urothelial cell carcinoma models
    Harm C Arentsen
    Department of Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    World J Urol 27:313-7. 2009
  10. ncbi Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs
    Kees Hendricksen
    Departments of Urology and Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 12:2597-601. 2006

Collaborators

Detail Information

Publications11

  1. pmc Two-year follow-up of the phase II marker lesion study of intravesical apaziquone for patients with non-muscle invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Inter Mail 659, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    World J Urol 27:337-42. 2009
    ..To study the time-to-recurrence and duration of response in non-muscle invasive bladder cancer (NMIBC) patients, with a complete ablative response after intravesical apaziquone instillations...
  2. doi The orthotopic Fischer/AY-27 rat bladder urothelial cell carcinoma model to test the efficacy of different apaziquone formulations
    Harm C Arentsen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Urol Oncol 30:64-8. 2012
    ..The objective of this study was to assess antitumor activity and safety of 3 different formulations of intravesical apaziquone in an orthotopic rat bladder cancer model...
  3. doi Comparison of three schedules of intravesical epirubicin in patients with non-muscle-invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur Urol 53:984-91. 2008
    ....
  4. doi Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer
    Rianne J M Lammers
    Radboud University Nijmegen Medical Center, Department of Urology, Nijmegen, The Netherlands
    Eur Urol 60:713-20. 2011
    ..Cigarette smoking is the most well-established risk factor for developing bladder cancer...
  5. doi Evaluation of an orthotopic rat bladder urothelial cell carcinoma model by cystoscopy
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    BJU Int 101:889-93. 2008
    ..To enable preclinical testing of intravesical therapies against non-muscle-invasive bladder cancer (NMIBC) in an orthotopic rat bladder tumour model, augmented by the use of serial cystoscopy for in vivo tumour assessment and follow-up...
  6. ncbi Current strategies for first and second line intravesical therapy for nonmuscle invasive bladder cancer
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Curr Opin Urol 17:352-7. 2007
    ..We discuss options for first-line and second-line adjuvant therapy for nonmuscle invasive bladder cancer...
  7. ncbi Intravesical pharmacotherapy for non-muscle-invasive bladder cancer: a critical analysis of currently available drugs, treatment schedules, and long-term results
    J Alfred Witjes
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Eur Urol 53:45-52. 2008
    ..Review adjuvant intravesical pharmacotherapy for non-muscle-invasive bladder cancer (NMIBC), emphasising treatment schedules and long-term results...
  8. ncbi Intravesical gemcitabine: an update of clinical results
    Kees Hendricksen
    Department of Urology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Curr Opin Urol 16:361-6. 2006
    ..In search for efficacy improvement and side effect reduction, we reviewed the promising properties of the relatively new intravesical drug, gemcitabine...
  9. pmc Experimental rat bladder urothelial cell carcinoma models
    Harm C Arentsen
    Department of Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    World J Urol 27:313-7. 2009
    ..In the second part of the paper the development of a potential new orthotopic rat bladder tumor model is described...
  10. ncbi Potential and toxicity of intravesical pemetrexed: a preclinical study in pigs
    Kees Hendricksen
    Departments of Urology and Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands
    Clin Cancer Res 12:2597-601. 2006
    ..In search for a new drug for intravesical use in superficial urothelial cell carcinoma of the bladder, a pig model is used for pharmacokinetics and toxicity measurements after intravesically administered pemetrexed...
  11. pmc Intravesical hyperthermia and mitomycin-C for carcinoma in situ of the urinary bladder: experience of the European Synergo working party
    J Alfred Witjes
    Department of Urology, Radboud University Nijmegen Medical Centre, PO Box 9101, Nijmegen 6500 HB, The Netherlands
    World J Urol 27:319-24. 2009
    ..To study the results of chemotherapy combined with intravesical hyperthermia in patients with mainly BCG-failing carcinoma in situ (CIS)...